The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

Eli Lilly has followed through on its ... study in 643 patients showed no impact of the drug on scales used to monitor cognition in Alzheimer's patents overall, although Cortexyme maintains ...

Eli Lilly has backed away from plans to file Alzheimer's drug donanemab in the first quarter of this year, saying the proposal to limit reimbursement of Biogen's first-to-market Aduhelm has made ...

Many Alzheimer’s experts were dismayed — but ... Three others received consulting fees from Eli Lilly, Biogen, and Eisai, among other drug makers active in the AD field. One author is a ...

Antimicrobials, vaccines, and anti-inflammatories are associated with a reduced risk for Alzheimer disease and dementia.

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

Eli Lilly and Company (NYSE ... as well as people with the mild dementia stage of Alzheimer's disease who have confirmed amyloid pathology.1,2 The Egyptian Drug Authority approved the insulin ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) revealed long-term study results indicating that over 80% of adults and adolescents with moderate-to-severe atopic dermatitis... ByInvesting ...